Last reviewed · How we verify
CurePML - Allogeneic HPyV-2-specific T-cell Therapy in Patients With Progressive Multifocal Leukoencephalopathy
There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in this study. The sponsor wants to find out whether the IMP is safe, influences the neurological status and improves the quality of the life of patients . It is to be investigated whether the IMP can be used to treat the disease and whether it could have an advantage over the standard therapy in terms of survival rate.
Details
| Lead sponsor | Hannover Medical School |
|---|---|
| Phase | Phase 2 |
| Status | RECRUITING |
| Enrolment | 23 |
| Start date | 2026-02-06 |
| Completion | 2027-11 |
Conditions
- Progressive Multifocal Leucoencephalopathy (PML)
Interventions
- Application of T-lymphocytes
Primary outcomes
- Demonstrate efficacy of treatment — 6 months after diagnosis
Determine proportion of patients surviving 6 months (overall survival) since diagnosis.
Countries
Germany